• Revenue: Q4 2023 saw a decrease of 34% year-over-year and 6% sequentially, with full-year revenue down 28%.

• Net Income: Attributable to common stockholders dropped by 77% in Q4 and 61% for the full year.

• Gross Profit Margin: Slightly declined by 20 basis points year-over-year and 10 basis points sequentially in Q4.

• Adjusted EBITDA: Experienced a significant decrease of 64% in Q4 and 52% for the full year.

• Diluted EPS: Fell to $0.26 in Q4 from $1.05 in the previous year, with full-year EPS also declining.

• Cash Flows from Operations: Increased by 179% in Q4 and 85% for the full year, indicating strong operational cash generation.

• Debt Position: Cross Country Healthcare ended the year debt-free, having repaid $73.9 million on the term loan.

• Warning! GuruFocus has detected 4 Warning Sign with CCRN.

On February 21, 2024, Cross Country Healthcare Inc (NASDAQ:CCRN) released its 8-K filing, detailing its financial results for the fourth quarter and full year ended December 31, 2023. The company, a leading provider of staffing, recruiting, and workforce solutions in the healthcare sector, reported a decline in both quarterly and annual revenue and net income. Despite these challenges, Cross Country Healthcare has made strategic investments in technology and ended the year with a strong balance sheet.

Financial Performance Overview

For the fourth quarter, Cross Country Healthcare reported revenue of $414.0 million, a 34% decrease from the same period last year, and a 6% sequential decrease from the third quarter of 2023. The full-year revenue amounted to $2.0 billion, marking a 28% year-over-year decline. The gross profit margin for Q4 was 21.9%, slightly down from the previous year, while the full-year margin was 22.3%.

Net income attributable to common stockholders for Q4 was $9.0 million, a significant drop from $38.8 million in the prior year. The full-year net income also saw a decrease, coming in at $72.6 million compared to $188.5 million in the previous year. Diluted earnings per share (EPS) for Q4 stood at $0.26, down from $1.05 in the prior year, with full-year EPS at $2.05, a decrease from $5.02.

Strategic Investments and Balance Sheet Strength

Cross Country Healthcare has proactively managed its cost structure, achieving a full-year adjusted EBITDA margin of over 7%. The company generated positive cash flow from operations of $12 million for the quarter and a record year of $249 million. These strong cash flows enabled the company to repay significant debt, ending the year debt-free.

The company has also invested more than $20 million in core technologies, including Intellify and XperienceTM, and repurchased 6.8% of shares outstanding for $57.6 million in 2023. President and CEO John A. Martins emphasized the company's pride in its accomplishments, including the rollout of Intellify and growth in non-travel businesses such as physician staffing, education, and homecare.